"Janus Kinase 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A Janus kinase subtype that is predominantly expressed in hematopoietic cells. It is involved in signaling from a broad variety of CYTOKINE RECEPTORS including ones that utilize the INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT.
| Descriptor ID |
D053616
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.124.300 D12.776.476.393.300
|
| Concept/Terms |
Janus Kinase 3- Janus Kinase 3
- Kinase 3, Janus
- JAK-3 Protein Tyrosine Kinase
- JAK 3 Protein Tyrosine Kinase
- JAK3 Protein Tyrosine Kinase
|
Below are MeSH descriptors whose meaning is more general than "Janus Kinase 3".
Below are MeSH descriptors whose meaning is more specific than "Janus Kinase 3".
This graph shows the total number of publications written about "Janus Kinase 3" by people in this website by year, and whether "Janus Kinase 3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Janus Kinase 3" by people in Profiles.
-
Liu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017 Oct; 77(4):675-682.e1.
-
Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, Yost A, Ma W, Fleischman AG, Zhou W, Yang Y, Kleppe M, Ahn Y, Tatarek J, Kelliher MA, Neuberg DS, Levine RL, Moriggl R, M?ller M, Gray NS, Jamieson CH, Weng AP, Staudt LM, Druker BJ, Look AT. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov. 2013 May; 3(5):564-77.
-
Huang JF, Yafawi R, Zhang M, McDowell M, Rittenhouse KD, Sace F, Liew SH, Cooper SR, Pickering EH. Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease. Ophthalmology. 2012 Jul; 119(7):e43-50.
-
Shi M, Lin TH, Appell KC, Berg LJ. Cell cycle progression following naive T cell activation is independent of Jak3/common gamma-chain cytokine signals. J Immunol. 2009 Oct 01; 183(7):4493-501.
-
Shi M, Lin TH, Appell KC, Berg LJ. Janus-kinase-3-dependent signals induce chromatin remodeling at the Ifng locus during T helper 1 cell differentiation. Immunity. 2008 Jun; 28(6):763-73.
-
Mayack SR, Berg LJ. Cutting edge: an alternative pathway of CD4+ T cell differentiation is induced following activation in the absence of gamma-chain-dependent cytokine signals. J Immunol. 2006 Feb 15; 176(4):2059-63.